New study confirms Dengvaxia poses more risks for kids without prior infection

A new study confirmed that Denkaksia, a controversial vaccine of Manila - Sanofi pasteur of the Philippines, poses additional risk to children not infected with dengue virus before vaccination

A recent study published in the New England Journal of Medicine confirmed the April recommendation of the World Health Organization that only infected children are registered in this country.

"A person who has been vaccinated before vaccination has severe VCD (virologically proved dengue) and VCD have been hospitalized for 5 years, and vaccinated people are not exposed to these results There is evidence, higher dengue, "the study said

According to this study, this vaccine can prevent cases of 11,000 hospitalizations and 2,500 severe dengue cases, and given more than 1 million children, it will lead to 1000 hospitalization and 500 severe dengue fever There is a possibility.

With a 95% confidence interval, the analysis shows that the dengue risk ratio is behind 1 point, prove that Denkaksia is better, a score above 1 means the vaccine is more dangerous.

The study also found that at 18 months after vaccination the risk of hospitalization for uninfected children from 2 to 8 years of age was high. At the same time, children between the ages of 9 and 16 have a higher risk of hospitalization after 30 months of vaccination.

The study funded by Sanofi included 2,384 participants who received Tenbo Summer Vaccination and 1,194 participants in the control group.

However, this study states that it is impossible to determine an "uncertain" accurate risk assessment because the baseline data is limited.

In November, sanofi's previous clinical data analysis revealed the risk of dengue vaccine. This new study supports sanofi's previous findings.

In the Philippines, the government implemented a school-based deng immunization program in several areas, sanofi's announcement led to public assault and anti-vaccine emotions

This plan was investigated in the Senate and the House of Commons, started in April 2016 and was suspended by the Ministry of Health in December 2017. (Schedule: Deng immunization program for students in public schools)

In addition to the Philippines, the release of vaccines has been approved in 10 countries, Brazil, Costa Rica, El Salvador, Guatemala, Mexico, Paraguay, Peru, Indonesia, Singapore and Thailand. - Rappler.com

"This analysis has confirmed that ensenza has a sustained protective effect against the dengue fever of previously infected people, but for those who have never been infected with dengue virus before, the analysis is long-term There may be more serious vaccination cases of illness, then dengue fever infection, "sanofi said

Dengue is the fastest growing mosquito-borne disease in the world today, with an estimated 1 million new infections per day. Severe dengue fever is generally rare and only 0.5% of all symptomatic cases occur, but the secondary infection of the virus is more likely to develop into a more serious disease than the first infection. This unique feature of dengue infection is important to understand the new data on dengue vaccines discussed in the New England Journal of Medicine article. This supplemental analysis showed that vaccinated individuals had a higher incidence of serious diseases without prior infection compared with those who were not vaccinated.

Dengvaxia®: We are confirming the preventive effect of at least one Dengue infected person; vaccination is not recommended for those who have not previously been infected

There are four kinds of dengue fever. When infected with one strain, the first Dengue infection is usually mild, then you will be immunizing specific strains in your life - but then if you infect the other three strains, It gets worse. There is a possibility of life threatening. Dengvaxia aims to prevent these serious infections by inoculating patients with four strains. The test showed that Levasia can reduce severe dengue cases by 90% in patients over 9 years of age and reduce the risk of dengue hospitalization by 80%